Pdc*Line Pharma
Novel class of off-the-shelf cancer immunotherapies based on a proprietary Plasmacytoid Dendritic Cell line pre-loaded with peptides
2
Funding Rounds
$43.9m
Money raised
Funding
Funding series
Funding Series Analysis
The company Pdc*Line Pharma has raised a total of $30.9m in funding over 2 rounds.
Key Insights:
- PDC*line pharma January 2024 Series B Funding Round: $8.7m
- Pdc*Line Pharma Series B round, January 2020: $22.2m
PDC*line pharma January 2024 Series B Funding Round
$8.7m
Pdc*Line Pharma Series B round, January 2020
$22.2m
Industries
Pdc*Line Pharma is active in the following industries: